3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
Radiotherapy
2
Paclitaxel
2
Carboplatin
2
talimogene laherparepvec
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Vorinostat
1
Trastuzumab
1
Taxes
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Radiation
1
Mastectomy, Segmental
1
Mastectomy
1
Mass Spectrometry
1
Immunohistochemistry
1
Gene Expression Profiling
1
Fulvestrant
1
Fluorescent Antibody Technique
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Counseling
1
Chromatography, Liquid
1
Brachytherapy
1
Anastrozole
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Ductal, Breast
×
Epirubicin
×
1 year
×
Clear all
No trials found.